I. Algarra, A. Garcia-lora, T. Cabrera, F. Ruiz-cabello, and F. Garrido, The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape, Cancer Immunol Immunother, vol.53, p.904, 2004.

H. Benlalam, V. Vignard, A. Khammari, A. Bonnin, Y. Godet et al., Infusion of Melan-A/Mart-1 speciWc tumor-inWltrating lymphocytes enhanced relapse-free survival of melanoma patients, Cancer Immunol Immunother, vol.56, issue.4, pp.515-526, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-02482050

T. Bonn, P. G. Coulie, B. J. Van-den-eynde, and P. Van-der-bruggen, Human T Cell responses against melanoma, Annu Rev Immunol, vol.24, p.175, 2006.

A. Dalgleish, The case for therapeutic vaccines, Melanoma Res, vol.6, p.5, 1996.

B. Dreno, J. M. Nguyen, A. Khammari, M. C. Pandolwbno, M. H. Tessier et al., Randomized trial of adoptive transfert of melanoma Tumor InWltrating Lymphocytes (TIL) as adjuvant therapy in melanoma stage III, Cancer Immunol Immunother, vol.10, p.539, 2002.

M. E. Dudley, J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian et al., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma, J Clin Oncol, vol.23, p.2346, 2005.

M. E. Dudley, J. R. Wunderlich, J. C. Yang, P. Hwu, D. J. Schwartzentruber et al., A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-speciWc T lymphocytes in patients with metastatic melanoma, J Immunother, vol.25, issue.3, p.243, 2002.

C. Estellat, Y. De-rycke, and B. Asselain, Intérêt et limites des analyses en sous-groupes dans les essais thérapeutiques "Mode d'emploi des analyses en sous-groupes, vol.7, p.75, 2005.

F. Garrido and I. Algarra, MHC antigens and tumor escape from immune surveillance, Adv Cancer Res, vol.83, p.117, 2001.

F. Jotereau, M. C. Pandolwno, D. Boudart, E. Diez, . Dreno-b et al., High-fold expansion of human cytotoxic T-lymphocytes speciWc for autologous melanoma cells for use in immunotherapy, J Immunother, vol.10, p.405, 1991.

Y. Kawakami, S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang et al., Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-inWltrating T lymphocytes associated with in vivo tumor regression, J Immunol, vol.154, p.3961, 1995.

K. Kono, H. Kawaida, A. Takahashi, H. Sugai, K. Mimura et al., CD4(+)CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers, Cancer Immunol Immunother, vol.55, p.1064, 2006.

N. Labarriere, M. C. Pandolwbno, N. Gervois, A. Khammari, M. H. Tessier et al., Therapeutic eYcacy of melanoma reactive TIL infused to melanoma stage III patients, Cancer Immunol Immunother, vol.10, p.532, 2002.

M. C. Pandolwno, N. Labarriere, M. H. Tessier, A. Cassidanius, S. Bercegeay et al., High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement, Cancer Immunol Immunother, vol.50, issue.3, p.134, 2001.

G. Quereux, M. C. Pandolwno, A. C. Knol, A. Khammari, C. Volteau et al., Tissue prognostic markers for adoptive immunotherapy in melanoma, Eur J Dermatol, vol.17, issue.4, 2007.

P. F. Robbins, M. E. Dudley, J. Wunderlich, M. El-gamil, Y. F. Li et al., Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy, J Immunol, vol.173, p.7125, 2004.

S. A. Rosenberg, P. Spiess, and R. Lafreniere, A new approach to the adoptive immunotherapy of cancer with tumor-inWltrating lymphocytes, Science, vol.233, p.1318, 1986.

F. Ruiz-cabello, T. Cabrera, M. A. Lopez-nevot, and F. Garrido, Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy, Semin Cancer Biol, vol.12, p.15, 2002.